Neurocrine Biosciences (NBIX) Fundamental Analysis: Revenue, Earnings & Valuation

4.00 / 10

Netural

Fundamental score is 4.0/10, indicating fair health. Inventory turnover (0.824) and cost‑of‑sales ratio (1.82%) are strong, while revenue growth (~21% YoY) is solid. Weaknesses include a low PB‑ROE (1.97) and negative asset‑MV, limiting upside.

Analysis Checks(9/10)

Revenue-MV

Value-0.51

Score3/3

Weight36.02%

1M Return8.11%

Total operating revenue (YoY growth rate %)

Value21.45

Score2/3

Weight0.49%

1M Return0.13%

Inventory turnover ratio

Value0.82

Score3/3

Weight-3.54%

1M Return-0.93%

Current liabilities / Total liabilities (%)

Value53.93

Score2/3

Weight1.39%

1M Return0.36%

PB-ROE

Value1.97

Score0/3

Weight12.13%

1M Return2.74%

Long-term debt to working capital ratio (%)

Value0.36

Score3/3

Weight3.15%

1M Return0.87%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight-4.18%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value21.45

Score2/3

Weight0.20%

1M Return0.05%

Cost of sales ratio (%)

Value1.82

Score3/3

Weight1.04%

1M Return0.26%

Asset-MV

Value-0.55

Score2/3

Weight53.28%

1M Return11.12%

Is NBIX undervalued or overvalued?

NBIX scores 4.00/10 on fundamentals and holds a Fair valuation at present. Backed by its 16.38% ROE, 16.73% net margin, 27.80 P/E ratio, 4.09 P/B ratio, and 41.47% earnings growth, these metrics solidify its Netural investment rating.